Drugs / BM230
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06644300 | Dec 2024 → Dec 2027 expected | cancer | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07698587 | Jul 2026 → Dec 2029 expected | cancer | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06644300 ↗ |
| Route | Subcutaneous | “Patients will be treated with BM230 subcutaneous (s.c.) injection” NCT06644300 ↗ |